The practical implementation and validation of a ligand-based approach to mining the chemogenomic space of drugs is presented and applied to the in silico target profiling of 767 drugs against 684 targets of therapeutic relevance. The results reveal that drugs targeting aminergic G protein-coupled receptors (GPCRs) show the most promiscuous pharmacological profiles. The detection of cross-pharmacologies between aminergic GPCRs and the opioid, sigma, NMDA, and 5-HT3 receptors aggravate the potential promiscuity of those drugs, predominantly including analgesics, antidepressants, and antipsychotics.
INTRODUCTION
In recent years, the capacity for synthesising and testing compounds has increased dramatically and screening campaigns of thousands of compounds against a single target are nowadays realistic, both within industrial and academic settings [1] . The total amount of unique compounds available for purchase from chemical providers is estimated at present to be close to eight million [2] . Therefore, with current screening capacities, experimental testing of the entire chemical space synthesised today against a particular target would still be feasible. However, current drug discovery is moving away from the traditional one drug -one target paradigm and focusing more towards identifying molecules that modulate multiple targets simultaneously [3] . Adding a biological dimension to high-throughput screening means that, even with the impressive technological advances made, current capacities are no longer sufficient to tackle the experimental testing of thousands of compounds against hundreds of targets.
Within this new scenario, in silico target profiling methods are emerging as efficient alternatives to the currently unaffordable high-throughput in vitro target profiling of compounds [4] . All these methods capitalize on the vast amount of prior knowledge available for many targets of therapeutic relevance, either by exploiting all bioactive ligands stored in annotated chemical libraries [5] or by using experimentally-determined crystal structures deposited in the Protein Data Bank [6] . Among some of the recently reported ligand-based methods, Nidhi et al. [7] exploited the contents of the WOMBAT annotated chemical library [8] to derive a multiple-category Laplacian-modified naïve Bayesian model that predicted the protein targets for all compounds in the MDDR database with a success rate of 77%, and Mestres et al. [9] used an in-house constructed library of 2033 mole-*Address correspondence to this author at the Chemotargets SL and Chemogenomics Laboratory, Research Unit on Biomedical Informatics, Institut Municipal d'Investigació Mèdica and Universitat Pompeu Fabra, Parc de Recerca Biomèdica, Doctor Aiguader 88, 08003 Barcelona, Catalonia, Spain; E-mail: jmestres@imim.es cules annotated to 25 nuclear receptors [10] to derive a similarity-based model that was able to recover the original annotations with a success rate of 71% and provide estimates of potential off-target affinities to nuclear receptors for several drugs. Among the most recent target-based methods, Rockey and Elcock [11] reported a method for rapidly computing the relative affinity of inhibitors to individual members of the kinase family, Kellenberger et al. [12] created a database of 6415 binding sites (sc-PDB) that was used to identify the native target of four unrelated ligands among the top 1% of scored binding sites, and Li et al. [13] have recently created a web server for inverse docking that allows for automatically screen small molecules over a panel of 698 protein structures covering 15 therapeutic areas. All these reports provide ample evidence for the possibilities of in silico target profiling methods in multitarget drug discovery.
One of the most promising possibilities is in the area of finding new therapeutic uses for approved drugs, an activity often referred to as drug repurposing [14] . Drugs have been traditionally designed to interact with a primary target known to be relevant to the particular disease of corporate interest. During the drug optimisation process, very limited scope was often given to address properly the issue of selectivity, by considering only a handful of additional targets phylogenetically related to the primary target. The ability of in silico target profiling methods to identify new targets for old drugs, as demonstrated recently by Keiser et al. [15] , has direct implications for using immediately off-patent products in clinical trials but also for alerting of potential secondary effects due to residual affinities for undesired targets [16] . Accordingly, the aim of this work is to probe the chemogenomic space of drugs by profiling in silico a set of 767 drugs against a panel of 684 targets representing all therapeutically-relevant protein families.
LIGAND-BASED PRIOR KNOWLEDGE
As stated above, in silico target profiling methods rely on the availability of prior knowledge on bioactive ligands and protein structures. In this contribution, focus will be given to a ligand-based method that currently exploits pharmacologi-cal data stored in three different annotated chemical libraries. [10] . Integrating all the data from these three different sources and filtering out all compounds having an activity value (K i , IC 50 , and/or EC 50 ) above 10 μM resulted in a total number of 109,766 unique compounds annotated to 684 targets. Table 1 presents the distribution of these 684 targets among 12 different target classes contained within 7 protein families, namely, enzymes, G protein-coupled receptors (GPCRs), ion channels, nuclear receptors, transporters, integrins, and catalytic receptors. The chemical space covering the family of enzymes contains 53,702 small molecules annotated to 411 enzymes which, in turn, are subdivided into 4 target classes, namely, proteases, kinases, cytochromes, and the rest, to reflect some of the enzyme subfamilies of main therapeutic relevance. In terms of chemical space coverage, GPCRs come next with 42,064 ligands annotated to 168 receptors which, in turn, are subdivided into 3 target classes, namely, aminergic, peptidic, and the rest, to reflect again some of the therapeutically most relevant GPCR subfamilies. The rest of the protein families are comparably smaller, both in terms of number of targets and chemical coverage. In essence, this will be the body of prior knowledge that will be subsequently used to derive the ligandbased protein models necessary to perform an in silico target profiling. Since the ability to extract knowledge from annotated chemical libraries will be highly determined by the way chemical and biological data are stored, special emphasis was put in storing both chemical structures and protein targets using appropriate unique identifiers and classification schemes [18] . For chemical structures, we used an in-house proposed Chemical Structure Code (CSC) purely based on topological features of molecules. Accordingly, each molecule was identified with a unique hierarchical five-level CSC [9] . The first and second levels are integers specifying, respectively, the number of rings in the largest ring system present in the molecule and the total number of ring systems in the molecule. The third, fourth, and fifth levels are a unique seven-character hash codes for the molecular framework, scaffold, and the complete molecular structure, respectively. For proteins, standard classification schemes were adopted directly when available or derived instead following the phylogenetic relationships among the members of the different protein families. For example, the Enzyme Commission number [19] was used for enzymes and the proposal from the Nuclear Receptor Nomenclature Committee [20] was used for nuclear receptors, whereas the classification scheme for GPCRs had to be derived from its internal phylogeny [21] .
LIGAND-BASED PROTEIN MODELS
The set of bioactive ligands collected for a given target provides in fact a complementary description of the target from a ligand viewpoint. In order to be able to process this information efficiently, molecular structures need to be encoded using some sort of mathematical descriptors. In this respect, we use a novel set of low-dimension molecular descriptors called SHED [22] . SHED are derived from distributions of atom-centered feature pairs extracted directly from the topology of molecules. Initially, each atom in a molecule is mapped to a Sybyl atom type and then assigned to one or more of four atom-centered features, namely, hydrophobic (H), aromatic (R), acceptor (A), and donor (D). For example, an aliphatic C.3 carbon will be assigned to a hydrophobic feature (H), whereas a protonated N.4h nitrogen will be assigned to both aromatic and donor features (R,D). Then, the shortest path length between atom-centered feature pairs is derived and its occurrence at different path lengths stored to create a feature-pair distribution. At this stage, Shannon entropies are used to quantify the degrees of occupancy and uniformity of each one of the ten distributions resulting from all pair combinations of the four features. In the end, each chemical structure is ultimately represented by a vector, referred to as its SHED profile, composed of 10 real numbers reflecting the particular feature-pair distributions present in the molecule. The ensemble of SHED profiles representing all molecules annotated to each particular target constitutes a mathematical description of the target from a ligand perspective.
Ligand-based descriptor models were derived for each one of the 684 targets with information on bioactive ligands. Prior to validating the sensitivity and specificity of the models, the criteria followed for annotating a query molecule to a given target needs to be defined. Therefore, the first step is to calculate the Euclidean distance between the SHED profile of the query molecule and all the target-related SHED profiles. The probability of a compound being active against that target is assumed to be related to the degree of similarity relative to the set of known bioactive ligands. Accordingly, the scoring of each compound in a chemical library with respect to a given target is assigned to the minimum value of all Euclidean distances. In the context of similarity-based virtual screening, the approach of combining the scores over multiple bioactive reference molecules has been recently referred to as group fusion and proven to give significantly superior results to using data fusion strategies on single reference molecules for a wide variety of protein targets [23] . If the minimum Euclidean distance is below a certain value, the molecule is annotated to that target. In this work, following a previous validation analysis [9] , the annotation threshold was set to a minimum Euclidean distance value of 0.6. This strategy follows on recent studies suggesting that similarity to molecules in the reference set is a good criteria for prediction accuracy of external test sets [24] .
Having clarified the process of target annotation to molecules, the degrees of recall and selectivity of the ligandbased models were assessed at a target class level. Table 2 summarises the confusion matrix resulting from processing all ligand-based target models of a particular target class (in columns) against all bioactive molecules of each target class (in rows). A leave-one-out procedure was enforced to avoid trivial annotations coming from collisions, implying that each molecule being processed was removed from the respective models. Values on the diagonal reflect the level of target-class recall of each model, that is, the proportion of target-class actives annotated by the target-class model. Offdiagonal values reflect mainly the level of target-class selectivity of each model, that is, the proportion of off-target-class actives annotated by the target-class model.
In general, good recall values are obtained, with percentages over 66% for 11 out of the 12 target classes. Only for the target class of catalytic receptors, with the lowest number of chemical information available, recall falls down to 59%. With respect to selectivity, the ligand-based model for proteases (pEC) is an example of a decent sensitive and selective model, with percentages of annotation to molecules bioactive to target classes other than proteases below 20%. A good selectivity pattern is also observed for the ligand-based model derived for cytochromes (cEC), with all crossannotation values under 12%. Interestingly, the ligand-based model for kinases (kEC) annotates also 31.9% and 45.1% of all actives to cytochromes and catalytic receptors (CR), although 34.7% of all actives to catalytic receptors were already annotated to kinases originally. In contrast, the ligandbased model for the 268 remaining enzymes (oEC) is clearly the most promiscuous model, with cross-annotation values above 30% for cytochromes, GPCRs other than aminergic and peptidic (oGR), nuclear receptors (NR), and catalytic receptors. Reasonable ligand-based models are also obtained for all three GPCR target classes. For aminergic GPCRs (aGR), the ligand-based model annotates also over 48% of all actives to transporters, an expected cross-annotation signal since 29.4% of them (essentially serotonin transporters) were already annotated to aminergic GPCRs. Also worth stressing is the generally good selectivity profiles obtained for the ligand-based models of both peptidic GPCRs (pGR) and GPCRs other than aminergic and peptidic (oGR). The remaining ligand-based models derived for nuclear receptors, ion channels (IC), transporters (TC), integrins (IN), and catalytic receptors show all low promiscuity levels, the only remark being that the nuclear receptor model annotates also over 30% of all actives to cytochromes. Therefore, overall, the analysis of the confusion matrix indicates that ligandbased protein models can indeed be a promising in silico approach to target profiling, with potential applicability in various fields such as targeted library design or drug repurposing.
IN SILICO TARGET PROFILING
With validated ligand-based models for 684 targets, we can now attempt estimating in silico the pharmacological profile of drugs to illustrate the scope of applicability for drug repurposing. Accordingly, a set of 767 drugs with known affinity for one or more targets was selected. After calculation of their respective SHED profiles, each drug was processed against all 684 ligand-based target models following the procedure described above. In total, we were able to assign at least a target annotation to 592 drugs, corresponding to 77.2% of the total number of drugs processed. Those 592 drugs received 3,728 annotations to 324 targets, which roughly means that on average each drug in this set was annotated to 11 targets. Out of the 3,728 annotations assigned, we were able to reproduce 998 of the original annotations, which represents an annotation recall of 55.1% (998 out of 1,810). The validity of many of the remaining 2,730 additional target annotations cannot be confirmed at this stage due to the lack of completeness in the activity data and, thus, a wealth of opportunities may be hiding there.
The annotations of each drug (in rows) to each target (in columns) are visually summarised in Fig. (1) . For the sake of clarity, labels have been added in columns to locate the regions covered by the 12 target classes. In the heatmap shown, cells colored within the red-to-yellow spectra mark the drug-target annotations. The color gradation between red and yellow reflects the value of the minimum SHED Euclidean distance between the SHED profile of each drug and the ensemble of SHED profiles annotated to each target. Accordingly, distance values close to 0.0 are represented in red, those close to 0.3 are seen in orange, and as distance values approach 0.6 they turn into yellow and finally green at values above the annotation threshold.
Looking at the heatmap in Fig. (1) from a drug perspective, perhaps the most significant observation is that the drugs that appear to be more promiscuous are by far those being annotated to aminergic GPCRs (aGR). To examine this aspect further, drugs were given a target promiscuity index according to the number of annotations assigned. A selection of the top 100 most promiscuous drugs with indices ranging from 34 to 15 is presented in Fig. (2) . Unfortunately, full assessment of the validity of these results cannot be performed because, as highlighted already above, activity Fig. (1) . The drug-target interaction heatmap. Annotations between drugs (in rows) and targets (in columns) are denoted by cells colored within the red-to-yellow spectra. Color gradation reflects distance to the closest bioactive reference: red, orange, and yellow reflect increasing distance values from 0.0 to 0.6; green means distances values above the annotation cut-off. See Table 1 for target class abbreviations. data available for drugs is not complete. Chlorpromazine is one of the few examples for which we have been able to confirm that it binds to 26 receptors with affinities (K i ) below 1 μM [3] . In our in silico target profiling exercise, chlorpromazine is found among the most promiscuous drugs (rank #6 of 592) with a promiscuity index of 31. Ranking drugs according to this target promiscuity index could be used as a means to estimate their liability due to residual offtarget affinities and thus anticipate potential side effects.
In this respect, we were able to identify two drugs that can be considered representative of the two possible scenarios. One of them is pergolide, a drug used for the treatment of Parkinson's disease that was recently withdrawn from the market due to latest findings of residual off-target affinity for 5-HT 2B , a serotonin receptor expressed in cardiac valves, the activation of which is known to be associated with developing drug-induced valvular heart disease [25] . Pergolide was originally designed as a dopaminergic D1/D2 agonist. However, when tested against an extended panel of aminergic GPCRs, it has a rather promiscuous profile with micromolar affinities for D 3 , D 4 , and D 5 dopamine receptors, as well as for the 5-HT 1A, 5-HT 1B , 5-HT 1D, 5-HT 2A , 5-HT 2B and 5-HT 2C serotonin receptors [26] . The results of our in silico target profiling of pergolide are summarised in Fig. (3) . Next to the structure of pergolide, the structures of the 5 annotated reference compounds having a SHED Euclidean distance below the annotation cut-off of 0.6 have been collected and their respective literature-extracted annotations shown. For example, the closest compound to pergolide was found at a distance of 0.29 and reported to be active to dopamine D 2 and serotonin 5-HT 1A . Therefore, these two annotations will be assigned to pergolide and the two of them can be confirmed experimentally. Overall, pergolide received 6 annotations to dopamine D 2 , D 3 , and D 4 , serotonin 5-HT 1A, 5-HT 1B , 5-HT 1D for which experimental evidence could be found [26] . But, in addition to those, 3 plausible annotations to the , , and μ opioids were assigned, for which we were unable to find confirmation in the literature. Regrettably, we were unable to annotate pergolide to 5-HT 2B . In spite of this, in silico target profiling provided a clear signal that pergolide could have residual affinities for at least 3 serotonin receptors. Knowing the intrinsic promiscuity of serotonin receptors, that signal could have triggered an early alert to test pergolide against a panel of serotonin receptors, which could have lead to a much earlier detection of the unwanted 5-HT 2B agonism. The other drug is celecoxib, a drug used to control the pain and inflammation associated with chronic inflammatory diseases such as rheumatoid-and osteo-arthritis. Celecoxib was originally conceived as a selective COX-2 inhibitor. The results of our in silico target profiling of celecoxib are summarised in Fig. (4) . For this drug, only two compounds were found to have a SHED Euclidean distance below the annotation cutoff. The closest one is in fact a structural analogue of celecoxib and is the one responsible for annotating the drug to COX-2. But most interestingly, just under 0.6, a compound active to carbonic anhydrase II (CA-II) is found and, consequently, this annotation is transferred to celecoxib. Providentially, clear evidence could be found in the literature, not only reporting that celecoxib was indeed a nanomolar inhibitor of CA-II but also providing a crystal structure of the interaction of celecoxib in the active site of CA-II [27] . In this case, the CA-II annotation assigned to celecoxib is an example of how in silico target profiling can provide new opportunities for old drugs.
Looking at the heatmap in Fig. (1) from a target perspective, one can clearly detect a similar pharmacological pattern among drugs for targets belonging to different target classes. Perhaps the most striking pattern observed is the crosspharmacology signal obtained between aminergic GPCRs, some peptidic GPCRs (opioid and sigma receptors), and some ion channels (NMDA and 5-HT 3 receptors). Beyond any phylogenetic relationship, these targets appear to be related pharmacologically by the fact that drugs active on any of them may be likely to have some residual affinity for the others. Evidences of cross-pharmacologies involving these receptors are plentiful in the literature. One example is the antitussive dextromethorphan, the neuroprotective properties of which have been recently associated to its action as NMDA receptor antagonist, sigma-1 receptor agonist, and voltage-gated calcium channel antagonist [28] . Another concrete example is the analgesic tramadolol, which has been shown to have micromolar affinities for the muscarinic M 1 and M 3 , serotonin 5-HT 2C , opioid receptors, and the NMDA receptor, a multi-receptor profile that might shed some light into elucidating the mechanism of action of its analgesic effect [29] . And a more generic example can be found in the fact that structurally different types of antidepressants (such as imipramine and mirtazepine) and antipsychotics (such as clozapine and haloperidol), commonly thought to exert their pharmacological action mainly through dopamine and serotonin receptors, have been proven to be functional antagonists at the ligand-gated ion channel serotonin 5-HT 3 receptor [30, 31] .
The pharmacological network established between the aminergic GPCRs, the opioid and sigma peptidic GPCRs, and the NMDA and 5-HT 3 ligand-gated ion channels is illustrated in Fig. (5) . In order to enhance the target connectivity signal, the network was constructed by linking all targets sharing at least ten drugs. The center and most connected part of the network is composed by all aminergic GPCRs (in dark green). This is in good agreement with a previous analysis suggesting that aminergic GPCRs are among the most promiscuous human proteins [32] . In turn, aminergic GPCRs appear highly connected, on one side, to opioid and sigma receptors (in light green) and, on the other side, to NMDA (in grey) and 5-HT 3 (in white). Although to a much lesser extent, connections between aminergic GPCRs and other GPCRs (light blue), cytochromes (yellow), kinases (red), as well as other enzymes (brown), are also visible. The family of nuclear receptors (dark blue) is the only target class disconnected from the rest, again very much in agreement with previous findings [32] .
CONCLUSION
The generation of safer and more efficacious drugs for the treatment of diseases is one of the main concerns in current pharmaceutical research. In part, this involves the ability of anticipating the pharmacological profile of drug candidates across multiple targets. In this respect, the capacity of high-throughput screening technologies for testing thousands of small molecules against hundreds of protein targets is still nowadays limited and thus novel in silico target profiling methods are emerging as a cost-effective alternative to reduce both the chemical and biological space to explore experimentally. Among those, this work has explored the performance of a ligand-based approach to predict the pharmacological profile of drugs. The results are highly encouraging, as demonstrated for the concrete cases of pergolide and celecoxib. In addition, cross-pharmacologies among proteins belonging to different target classes were detected, some of which could be confirmed in the scientific literature. Although the recall and selectivity rates evidence that there is still room for improvement, a detailed analysis of all the target annotations assigned might bring in the near future interesting new uses for old drugs. Further research in this direction is underway in our laboratory.
